AEvit in complex treatment of acne patients

Abstract

Objective — to assess the effectiveness and tolerability of AEvit in the complex treatment of patients with acne.Materials and methods. We observed 100 patients with acne. All patients were randomly assigned to the main (50 patients) and control (50 patients) groups. Inclusion criteria were: age from 18 to 40 years; diagnosis of acne in papulo­pustular form of light or moderate severity (2—4 scores on B.S. Allen and J.G. Smith’s scale).All the patients were examined using the following methods: examination of the skin of the face, chest, back, assessment of the intensity of the inflammatory process, calculation of the elements of the rash, assessment of the severity of acne on B.S. Allen and J.G. Smith’s scale and consideration of subjective feelings of the patient, general and biochemical blood test, general urine test. Patients with acne received standard therapy. Patients of the main group were additionally prescribed AEvit 1 capsule per day after meals during 30 days.Statistical processing of the obtained results was carried out using the methods of biometric analysis implemented in the packages of licensed programs Еxcel­2003® and Statistica 6.1 (StatSoftInc., serial number AGAR909E415822FA).Results and discussion. In 23 (46.0 %) patients of the control and 28 (56.0 %) patients of the main group, the disease duration ranged from 1 to 5 years. In 15 (30.0 %) patients of the main group and 17 (34.0 %) patients of the control group the disease lasted from 6 to 10 years, and in 12 (24.0 %) patients of the main group and 5 (10.0 %) patients of the control group the disease duration was of up to 1 year. Assessment of the severity of acne on B.S. Allen and J.G. Smith’s scale was performed on 10th, 21st and 30th days of the complex treatment. Prior to treatment, the severity of acne on B.S. Allen and J.G. Smith’s scale in the main group was (3.83 ± 0.42) scores, and in the control group — (3.79 ± 0.34) scores. After treatment, the severity of acne significantly decreased in the main group to (1.43 ± 0.65) scores and in the control group — to (2.31 ± 0.18) scores.Conclusions. According to the results of the analysis, in both groups there was a statistically significant decrease in the severity of acne symptoms, the number of rash elements, the severity of acne, but in the group of patients receiving AEvit it was more pronounced.